Wall Street analysts expect RadNet Inc. (NASDAQ:RDNT) to post $0.24 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for RadNet’s earnings, with the highest EPS estimate coming in at $0.28 and the lowest estimate coming in at $0.19. RadNet reported earnings of $0.13 per share during the same quarter last year, which would suggest a positive year over year growth rate of 84.6%. The business is scheduled to issue its next earnings results on Thursday, March 14th.

On average, analysts expect that RadNet will report full year earnings of $0.30 per share for the current financial year, with EPS estimates ranging from $0.25 to $0.34. For the next financial year, analysts forecast that the firm will report earnings of $0.52 per share, with EPS estimates ranging from $0.41 to $0.63. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that follow RadNet.

RadNet (NASDAQ:RDNT) last released its quarterly earnings results on Friday, November 9th. The medical research company reported $0.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.05). The company had revenue of $242.10 million during the quarter, compared to analysts’ expectations of $240.07 million. RadNet had a negative net margin of 0.44% and a positive return on equity of 14.62%. RadNet’s revenue was up 6.4% on a year-over-year basis. During the same period last year, the firm posted $0.12 earnings per share.

Several research analysts have commented on RDNT shares. BidaskClub upgraded shares of RadNet from a “hold” rating to a “buy” rating in a report on Saturday, October 13th. Zacks Investment Research upgraded shares of RadNet from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a report on Wednesday, October 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $15.50.

In other news, insider Norman R. Hames sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, December 13th. The shares were sold at an average price of $12.68, for a total transaction of $63,400.00. Following the completion of the sale, the insider now owns 569,000 shares in the company, valued at approximately $7,214,920. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Norman R. Hames sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, December 20th. The stock was sold at an average price of $10.40, for a total transaction of $156,000.00. Following the sale, the insider now owns 559,000 shares of the company’s stock, valued at approximately $5,813,600. The disclosure for this sale can be found here. Insiders have sold a total of 35,000 shares of company stock valued at $407,950 in the last 90 days. Insiders own 7.56% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. United Services Automobile Association purchased a new stake in RadNet in the 2nd quarter valued at $156,000. RBF Capital LLC purchased a new stake in RadNet in the 3rd quarter valued at $205,000. Campbell & CO Investment Adviser LLC raised its position in RadNet by 151.0% in the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 28,427 shares of the medical research company’s stock valued at $428,000 after purchasing an additional 17,100 shares during the last quarter. Stone Ridge Asset Management LLC raised its position in RadNet by 16.6% in the 3rd quarter. Stone Ridge Asset Management LLC now owns 31,750 shares of the medical research company’s stock valued at $478,000 after purchasing an additional 4,528 shares during the last quarter. Finally, MetLife Investment Advisors LLC raised its position in RadNet by 52.8% in the 3rd quarter. MetLife Investment Advisors LLC now owns 32,149 shares of the medical research company’s stock valued at $484,000 after purchasing an additional 11,105 shares during the last quarter. Hedge funds and other institutional investors own 60.58% of the company’s stock.

Shares of RDNT stock opened at $11.27 on Friday. The company has a quick ratio of 1.12, a current ratio of 1.12 and a debt-to-equity ratio of 4.56. The company has a market capitalization of $541.93 million, a P/E ratio of 38.86, a price-to-earnings-growth ratio of 2.67 and a beta of 0.84. RadNet has a fifty-two week low of $9.65 and a fifty-two week high of $16.54.

About RadNet

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.

See Also: Quick Ratio

Get a free copy of the Zacks research report on RadNet (RDNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.